Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Cytosorbents (CTSO) over the last 8 years, with Q3 2025 value amounting to $403000.0.

  • Cytosorbents' Current Deferred Revenue changed N/A to $403000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $403000.0, marking a year-over-year change of. This contributed to the annual value of $596000.0 for FY2024, which is 5683.73% down from last year.
  • As of Q3 2025, Cytosorbents' Current Deferred Revenue stood at $403000.0.
  • In the past 5 years, Cytosorbents' Current Deferred Revenue registered a high of $1.9 million during Q4 2021, and its lowest value of $361000.0 during Q2 2025.
  • Its 5-year average for Current Deferred Revenue is $964424.9, with a median of $596000.0 in 2024.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 16736.46% in 2021, then tumbled by 5683.73% in 2024.
  • Quarter analysis of 5 years shows Cytosorbents' Current Deferred Revenue stood at $1.9 million in 2021, then decreased by 22.11% to $1.5 million in 2022, then fell by 8.96% to $1.4 million in 2023, then crashed by 56.84% to $596000.0 in 2024, then tumbled by 32.38% to $403000.0 in 2025.
  • Its Current Deferred Revenue was $403000.0 in Q3 2025, compared to $361000.0 in Q2 2025 and $546028.0 in Q1 2025.